SERMs and SERMs with estrogen for postmenopausal osteoporosis (Q37743272)

22 August 2017

1 reference

title

SERMs and SERMs with estrogen for postmenopausal osteoporosis (English)

1 reference

22 August 2017

0 references

Michael A Bolognese

1

1 reference

22 August 2017

publication date

1 December 2010

1 reference

Reviews in Endocrine and Metabolic Disorders

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

253-259

1 reference

Prevalence of low femoral bone density in older U.S. adults from NHANES III.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

FRAX and its applications to clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Bone mineral density thresholds for pharmacological intervention to prevent fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Occurrence of stroke with tamoxifen in NSABP B-24

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Safety assessment of raloxifene over eight years in a clinical trial setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Raloxifene effect on frequency of surgery for pelvic floor relaxation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Effect of raloxifene on urinary incontinence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Cognitive function in postmenopausal women treated with raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

What can be learned from the levormeloxifene experience?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

High-resolution MRI and micro-FE for the evaluation of changes in bone mechanical properties during longitudinal clinical trials: application to calcaneal bone in postmenopausal women after one year of idoxifene treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Estrogen Receptors as Therapeutic Targets in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Urogenital effects of selective estrogen receptor modulators: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Lasofoxifene in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

A new approach to menopausal therapy: the tissue selective estrogen complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11154-010-9137-1

Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.

21 January 2018

1 reference

12 December 2020

A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women

1 reference

12 December 2020

Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene

1 reference

12 December 2020

Symptoms associated with tamoxifen treatment in postmenopausal women

1 reference

12 December 2020

Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy.

1 reference

12 December 2020

Selective estrogen receptor modulators: an update on recent clinical findings

1 reference

12 December 2020

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women

1 reference

12 December 2020

Effects of raloxifene hydrochloride on the endometrium of postmenopausal women

1 reference

12 December 2020

Adverse events reported by postmenopausal women in controlled trials with raloxifene

1 reference

12 December 2020

Estrogen receptors as therapeutic targets in breast cancer

1 reference

12 December 2020

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation

1 reference

12 December 2020

10.1007/S11154-010-9137-1

Identifiers

DOI

1 reference

22 August 2017

1 reference